# Dose-finding Study of LIK066 Compared With Placebo or Sitagliptin to Evaluate Change in HbA1c in Patients With Diabetes

> **NCT01824264** · PHASE2 · WITHDRAWN · sponsor: **Novartis Pharmaceuticals**

## Conditions studied

- Type 2 Diabetes Mellitus

## Interventions

- **DRUG:** LIK066
- **DRUG:** Sitagliptin
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01824264
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2015-11
- **Primary completion:** 2016-11
- **Final completion:** 2016-11
- **Target enrollment:** 0 (ACTUAL)
- **Last updated:** 2014-04-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01824264

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01824264, "Dose-finding Study of LIK066 Compared With Placebo or Sitagliptin to Evaluate Change in HbA1c in Patients With Diabetes". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT01824264. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*